相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells
Chang-xi He et al.
ACTA PHARMACOLOGICA SINICA (2014)
SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo
Lu Wang et al.
CANCER LETTERS (2014)
Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer
Ichiro Kawada et al.
CANCER RESEARCH (2014)
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
Roger B. Cohen
CANCER TREATMENT REVIEWS (2014)
Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes
Huiyun Pan et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2014)
Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models.
Katarzyna Wnuk-Lipinska et al.
CLINICAL CANCER RESEARCH (2014)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation
Dominic Leiser et al.
FEBS LETTERS (2014)
The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells
Alessandra Gentile et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The novel kinase inhibitor EMD1214063 is effective against neuroblastoma
Kathy Scorsone et al.
INVESTIGATIONAL NEW DRUGS (2014)
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
Sabine Kayser et al.
LEUKEMIA & LYMPHOMA (2014)
Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment
Yuen-Keng Ng et al.
MELANOMA RESEARCH (2014)
The receptor tyrosine kinase ROR1-An oncofetal antigen for targeted cancer therapy
Mohammad Hojjat-Farsangi et al.
SEMINARS IN CANCER BIOLOGY (2014)
SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-MET-Dependent Neoplastic Effects and Exerts Antitumor Activity
Hao-tian Zhang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells
Magali Humbert et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
Eric I. Zimmerman et al.
BLOOD (2013)
Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer
Patrick O'Donnell et al.
BMC CANCER (2013)
A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
Erica L. Mayer et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Distinct Effects of Ligand-Induced PDGFRα and PDGFRβ Signaling in the Human Rhabdomyosarcoma Tumor Cell and Stroma Cell Compartments
Monika Ehnman et al.
CANCER RESEARCH (2013)
Inhibition of Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
Wenjuan Wu et al.
CLINICAL CANCER RESEARCH (2013)
EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Friedhelm Bladt et al.
CLINICAL CANCER RESEARCH (2013)
Targeting MET: why, where and how?
Elena Ghiso et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
Devron R. Shah et al.
DRUG SAFETY (2013)
Promising New Molecular Targeted Therapies in Head and Neck Cancer
Kelly Dorsey et al.
DRUGS (2013)
First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
Bin-Chi Liao et al.
DRUGS (2013)
Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets
William C. S. Cho et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
Michael R. Grunwald et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Cancer Development, Progression, and Therapy: An Epigenetic Overview
Sibaji Sarkar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
S. Betty Yan et al.
INVESTIGATIONAL NEW DRUGS (2013)
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants
Michaela Medova et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro et al.
LANCET ONCOLOGY (2013)
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
Amir Hossein Daneshmanesh et al.
LEUKEMIA & LYMPHOMA (2013)
被撤回的出版物: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells (Retracted article. See vol. 17, 2022)
Mohammad Hojjat-Farsangi et al.
PLOS ONE (2013)
Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Mary E. Irwin et al.
PLOS ONE (2013)
The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells
Mohammad Hojjat-Farsangi et al.
PLOS ONE (2013)
The molecular basis of targeting protein kinases in cancer therapeutics
Chung-Jung Tsai et al.
SEMINARS IN CANCER BIOLOGY (2013)
MET: A Critical Player in Tumorigenesis and Therapeutic Target
Carrie R. Graveel et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance
Kyle W. Robinson et al.
CURRENT ONCOLOGY REPORTS (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
ADME of Biologics-What Have We Learned from Small Molecules?
Thomayant Prueksaritanont et al.
AAPS JOURNAL (2012)
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation
Yao Dai et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors
Michael C. Heinrich et al.
CLINICAL CANCER RESEARCH (2012)
Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer
Nikolaos Ioannou et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2012)
Novel targeted agents for the treatment of advanced breast cancer
Maximo de la Vega et al.
FUTURE MEDICINAL CHEMISTRY (2012)
Cediranib: a VEGF receptor tyrosine kinase inhibitor
Marina Sahade et al.
FUTURE ONCOLOGY (2012)
Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
Hans-Joachim Schmoll et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
Rodrigo Dienstmann et al.
MOLECULAR ONCOLOGY (2012)
Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells
A. H. Daneshmanesh et al.
LEUKEMIA (2012)
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
Fenlai Tan et al.
LUNG CANCER (2012)
MET: a promising anticancer therapeutic target
Solange Peters et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies
Shubha Bagrodia et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Suping Zhang et al.
PLOS ONE (2012)
Anticancer molecules targeting fibroblast growth factor receptors
Guang Liang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Flavio Solca et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy
Asish K. Ghosh et al.
BLOOD (2011)
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
Z. A. Wainberg et al.
BRITISH JOURNAL OF CANCER (2011)
Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer
Louise R. Howe et al.
CANCER PREVENTION RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
Lee S. Rosen et al.
CLINICAL CANCER RESEARCH (2011)
Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1,-2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
Ferry A. L. M. Eskens et al.
CLINICAL CANCER RESEARCH (2011)
Selectivity Filters to Edit Out Deleterious Side Effects in Kinase Inhibitors
Sean Sessel et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
Aberrant Expression of c-Met and HGF/c-Met Pathway Provides Survival Advantage in B-Chronic Lymphocytic Leukemia
Emel Eksioglu-Demiralp et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2011)
BIBW 2992 in non-small cell lung cancer
Deepa S. Subramaniam et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
A Novel Mode of Protein Kinase Inhibition Exploiting Hydrophobic Motifs of Autoinhibited Kinases DISCOVERY OF ATP-INDEPENDENT INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR
Sudharshan Eathiraj et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
Qiong Zhao et al.
LUNG CANCER (2011)
Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib
Vince D. Cataldo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer
Eunice Kwak
ONCOLOGIST (2011)
Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
Pankaj Bhargava et al.
CURRENT ONCOLOGY REPORTS (2011)
Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence
Daniel V. T. Catenacci et al.
CANCER DISCOVERY (2011)
Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo
Agnes Jaeger-Lansky et al.
CANCER BIOLOGY & THERAPY (2010)
R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
Sacha J. Holland et al.
CANCER RESEARCH (2010)
The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo
Julian Paesler et al.
CLINICAL CANCER RESEARCH (2010)
Non-ATP Competitive Protein Kinase Inhibitors
L. Garuti et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
Rachel Ma Linger et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
Neru Munshi et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases
Jasmine V. Abella et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
Keith W. Pratz et al.
BLOOD (2009)
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
Yukimasa Shiotsu et al.
BLOOD (2009)
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
Olivier Rixe et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix A Gynecologic Oncology Group Study
Russell J. Schilder et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317
Michael S. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers
Nancy L. Lewis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Protein kinase inhibitors: contributions from structure to clinical compounds
Louise N. Johnson
QUARTERLY REVIEWS OF BIOPHYSICS (2009)
Seizure activity post organophosphate exposure
John Tattersall
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis
Caroline A. Heckman et al.
CANCER RESEARCH (2008)
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
David L. Shattuck et al.
CANCER RESEARCH (2008)
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model
Eri Taguchi et al.
CANCER SCIENCE (2008)
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
Stuart Thomson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
Sivasubramanian Baskar et al.
CLINICAL CANCER RESEARCH (2008)
Role of platelet-derived growth factors in physiology and medicine
Johanna Andrae et al.
GENES & DEVELOPMENT (2008)
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
Amir H. DaneshManesh et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Andrea J. Gonzales et al.
MOLECULAR CANCER THERAPEUTICS (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer
Pasi A. Jaenne et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
Y. Minami et al.
ONCOGENE (2007)
Her signaling in pancreatic cancer
Barbara Burtness
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
X. Jiang et al.
LEUKEMIA (2007)
Receptor tyrosine kinases: mechanisms of activation and signaling
Stevan R. Hubbard et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia
Mahdi Shabani et al.
TUMOR BIOLOGY (2007)
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs
Mayumi Ono et al.
CLINICAL CANCER RESEARCH (2006)
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J. DeAngelo et al.
BLOOD (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties
Kazuhide Nakamura et al.
CANCER RESEARCH (2006)
Opinion -: Invasive growth:: a MET-driven genetic programme for cancer and stem cells
Carla Boccaccio et al.
NATURE REVIEWS CANCER (2006)
A physiologic imaging pilot study of breast cancer treated with AZD2171
KD Miller et al.
CLINICAL CANCER RESEARCH (2006)
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer
S Campos et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity
HR Tsou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects
AK Bence et al.
INVESTIGATIONAL NEW DRUGS (2005)
Death receptors in chemotherapy and cancer
KM Debatin et al.
ONCOGENE (2004)
Normal and oncogenic FLT3
T Naoe et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
Timeline - Gefitinib - a novel targeted approach to treating cancer
RS Herbst et al.
NATURE REVIEWS CANCER (2004)
Review of epidermal growth factor receptor biology
RS Herbst
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells
R Bansal et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2003)
The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D
CA Love et al.
NATURE STRUCTURAL BIOLOGY (2003)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
LM Kelly et al.
CANCER CELL (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
Receptor tyrosine kinase signalling as a target for cancer intervention strategies
E Zwick et al.
ENDOCRINE-RELATED CANCER (2001)
Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases
A Östman et al.
TRENDS IN CELL BIOLOGY (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
RTK mutations and human syndromes - when good receptors turn bad
SC Robertson et al.
TRENDS IN GENETICS (2000)
Epigenetic determinants of resistance to etoposide regulation of Bcl-xL and Bax by tumor microenvironmental factors
ST Taylor et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
